Clinical Trial Update: Study Evaluating DNA Double-strand Breaks (DSBs) REpair Factors (POLQ, Shieldin Complex and 53BP1) Expression as Biomarker of PARP Inhibitor Resistance in Patients With Deleterious Germline Mutation in BRCA 1/2 and HER2-negative, Metastatic or Locally Advanced Breast Cancer. [NA]

View source ↗

Summary

This clinical trial is investigating expression of DNA double-strand break repair factors (POLQ, Shieldin complex, and 53BP1) as biomarkers for PARP inhibitor r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Snippet

Sponsor: Institut Claudius Regaud | Conditions: Breast Cancer | NA | Status: RECRUITING